Matthew Harrison

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) jumped in early trading on Wednesday, after the company reported an earnings beat for its fourth quarter. Information shared by management following the mid-cycle review of SRP-9001 increases the confidence in its early approval, according to Morgan...

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen Analyst Brian Abrahams maintained an Outperform rating, while raising the price...

Moderna, Inc. (NASDAQ: MRNA) rose to prominence with its messenger RNA-based COVID-19 vaccine. The stock capitalized on the catalyst and ran up from obscurity to respectable levels. The stock rally has cooled amid fears regarding the sustainability of the strength induced by the COVID-19...

The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a handful of biopharma stocks, according to a Morgan Stanley analyst.  The Biopharma Analyst: Matthew Harrison maintained an Equal-Weight rating...

Moderna, Inc.'s (NASDAQ: MRNA) vaccine franchise has further legs to play out, according to an analyst at Morgan Stanley. The Moderna Analyst: Matthew Harrison has an Equal-weight rating and a $313 price target for Moderna shares. The Moderna Thesis: The success of COVID-19 mRNA vaccines...

Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm. Notwithstanding the still-raging debate over the decision, an analyst at Morgan Stanley is looking past the decision and into key upcoming catalysts that could provide significant...

Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over 38%.  The Biogen Analysts: Morgan Stanley analyst Matthew Harrison maintained an Overweight rating on Biogen shares and increased the price target from...

Gilead Sciences, Inc. (NASDAQ: GILD) and its R&D partner Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) received an upgrade each from Morgan Stanley. The Gilead, Galapagos Analyst: Matthew Harrison upgraded Gilead from Equal-weight from Overweight and increased the price target from $67 to...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in the new year, are sinking. What Happened: Cambridge, Massachusetts-based Sarepta announced topline results from Part 1 of the Phase 2/3 study of...

A day ahead of an FDA panel meeting for Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate, an analyst at Morgan Stanley stepped to the sidelines on the stock.  The Moderna Analyst: Matthew Harrison downgraded Moderna from Outperform to Equal-weight and raised the price...

Biogen Inc (NASDAQ: BIIB) shares saw a nice 40% bump Wednesday following the release of FDA briefing document prepared for Friday's Adcom meeting to discuss aducanumab BLA. Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and $357 price target. BofA Securities...

A successful COVID-19 vaccine could be a bumper revenue opportunity for the pharmaceutical companies, with the market estimated to generate at least $10 billion in revenue a year, according to analysts. The Thesis: Morgan Stanley and Credit Suisse analysts estimate that people will...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced positive preliminary Phase 1/2/3 results Tuesday for a study that evaluated its antibody cocktail REGN-COV2 in non-hospitalized coronavirus patients.  REGN-COV2 is composed of two anti-spike monoclonal antibodies that target...

Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc. (NASDAQ: IMMU), which recently transitioned to a commercial-stage biopharma following FDA approval of its antibody-drug conjugate Trodelvy as a third-line treatment for metastatic triple-negative...

Two Moderna Inc (NASDAQ: MRNA) analysts issued snapshots this week on the progress of the company's coronavirus vaccine program. The Moderna Analysts: SVB Leerink analyst Mani Foroohar maintained a Market Perform rating on Moderna with a $58 price target.  Morgan Stanley analyst...